AVALYN PHARMA INC

AVLNNASDAQ

🏆 #1879 by market capEarnings Sep 2US Equity

$35.46▲ $0.92 (+2.60%)

🌅 Pre-market$35.53▲ 0.20%Regular close · extended-hours price shown

1h—

24h▲ 2.6%

7d▲ 11.1%

14d▲ 26.4%

30d▲ 26.8%

1y—

🏦Market Cap

$1.57B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $35.31 – $35.72
52-Week Range: $24.15 – $35.20
Volume: $2.60B
Avg Volume: $1.90B
Shares Outstanding: 44.3M
Next Earnings: Oct 16, 2026

Fundamentals Snapshot

Annual Revenue: $162M
Last Q Revenue: $41M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): —
Dividend Yield: —

Why Investors Own AVLN

✓High-growth profile — revenue up +46.1% YoY with expanding US Equity exposure.
✓Healthy economics — 80% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$162M▲ +50.9% YoY

Gross Margin (TTM)

79.9%▲ +3.7% YoY

Operating Income (TTM)

$42M▲ +50.9% YoY

Free Cash Flow (TTM)

$13M▲ +50.9% YoY

About AVALYN PHARMA INC

Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

🦦